CKD-828 Telmisartan Non-Responder Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.

Also called NCT01426100

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 183 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01426100
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01426100. Randomized; triple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CKD-828 Telmisartan Non-Responder Trial
Condition
Hypertension
Intervention (Drug)
CKD-828 40/2.5mg
Intervention (Drug)
CKD-828 40/5mg
Intervention (Drug)
Telmisartan 80mg
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct01426100
Content hash
0712acd3dd15e8d2ddf0ab6eb00753758a189ee76aaad2cee529dcb87570697d